Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1Completed 1Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Leukemia, Myelogenous, Chronic, BCR-ABL Positive 10Leukemia, Myeloid, Chronic-Phase 4Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Myeloproliferative Disorders 1Malignant Solid Tumors 1Leukemia, Myeloid 1Leukemia 1Burkitt Lymphoma 1Bronchiolitis Obliterans Syndrome 1Blast Crisis 1

Interventions

venetoclax 22Cyclophosphamide 14Cytarabine 12Azacitidine 8fludarabine 7Daunorubicin 5ruxolitinib 4revumenib 4Trimethoprim, Sulfamethoxazole Drug Combination 4Dexamethasone 4quizartinib 3pirtobrutinib 3gamma-Globulins 3fludarabine phosphate 3blinatumomab 3Tacrolimus 3Rituximab 3Palliative Care 3Granulocyte Colony-Stimulating Factor 3Decitabine 3Ciprofloxacin 3Blood Specimen Collection 3zanubrutinib 2pembrolizumab 2ibrutinib 2aldesleukin 2acalabrutinib 2Watchful Waiting 2Mycophenolic Acid 2Melphalan 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Leukemia × asciminib × Clear all
NCT07354074 2026-05-26

Study to Determine the Efficacy and Safety of Asciminib in Pediatric Patients With Ph+ CML-CP

Novartis

Phase 2 Recruiting
50 enrolled
MyeloidOther hematologic neoplasm

Bronchiolitis Obliterans Syndrome, Leukemia, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Data powered by HemOnc (CC BY 4.0) Colophon âš¡